GlassScriptPhysician profile
Zia U Din
NPI 1396740171
$2,216.65
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,004 · 2020: $706 · 2021: $367 · 2022: $139.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $334.76 | 2019-2021 | |
| Vifor Pharma, INC. | $240.00 | 2019-2022 | |
| Akebia Therapeutics INC | $222.09 | 2019-2022 | |
| Amgen INC. | $201.22 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $199.84 | 2019-2021 | |
| Glaxosmithkline, LLC. | $140.61 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $131.45 | 2019 | |
| Mallinckrodt Hospital Products INC. | $107.51 | 2020-2021 | |
| Fresenius USA Marketing, INC. | $97.26 | 2019-2022 | |
| Mallinckrodt Enterprises LLC | $87.96 | 2019 | |
| Daiichi Sankyo INC. | $86.29 | 2019-2021 | |
| Opko Pharmaceuticals, LLC | $78.30 | 2019-2020 | |
| Horizon Therapeutics Plc | $66.02 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.55 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.50 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $20.89 | 2022 | |
| Hikma Pharmaceuticals USA | $18.91 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $18.53 | 2021 | |
| Arbor Pharmaceuticals, INC. | $18.12 | 2019 | |
| Melinta Therapeutics, LLC | $17.82 | 2019 | |
| Alexion Pharmaceuticals, INC. | $16.28 | 2021 | |
| Nxstage Medical, INC. | $16.00 | 2019 | |
| Aurinia Pharma U.S., INC. | $14.44 | 2022 | |
| Novartis Pharmaceuticals Corporation | $13.84 | 2020 | |
| Strongbridge US INC. | $11.46 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zia Din listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.